Thyroidectomy Surgery in India and UAE | Complete Patient Guide

• ELIGIBLE CANDIDATES (Surgical Indications):

• Confirmed or highly suspicious thyroid malignancy: Bethesda Category V (suspicious for malignancy) or VI (malignant) on FNAC cytology

• Differentiated thyroid carcinoma (papillary or follicular) of any size with high-risk features per ATA 2015 guidelines

• Medullary thyroid carcinoma (MTC) — hereditary (RET proto-oncogene mutation) or sporadic

• Goiter causing compressive or obstructive symptoms: tracheal deviation >1 cm, dysphagia, dyspnea, SVC compression

• Graves' disease or toxic multinodular goiter (TMNG) refractory to antithyroid drugs (ATDs) or radioiodine, or where RAI is contraindicated (e.g., active ophthalmopathy, pregnancy planning)

• Substernal or retrosternal goiter with mediastinal extension

• Bethesda Category III–IV nodules on repeat cytology where molecular testing (ThyroSeq v3, Afirma GSC) yields high-risk or indeterminate results

• Rapid nodule growth or calcification pattern suspicious on high-resolution ultrasound (TIRADS 4–5)

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• High-resolution neck ultrasound with nodule mapping and bilateral cervical lymph node evaluation

• Ultrasound-guided FNAC with Bethesda cytology classification

• Molecular marker panel where applicable: ThyroSeq v3, Afirma Gene Sequencing Classifier (GSC), BRAF V600E mutation testing (for PTC risk stratification)

• Serum TSH, Free T3, Free T4, Anti-TPO, Anti-TG antibodies

• Serum calcitonin and CEA (mandatory for MTC suspicion or exclusion)

• 24-hour urinary catecholamines / plasma metanephrines (to exclude concurrent pheochromocytoma in MEN2 before surgery)

• Laryngoscopy (flexible fiberoptic nasolaryngoscopy) for baseline vocal cord mobility assessment

• CT neck and chest with IV contrast (for substernal extension, tracheal compression, or suspected retropharyngeal involvement)

• Baseline serum calcium, phosphate, PTH, and 25-OH Vitamin D

• Standard pre-anesthetic workup: ECG, CBC, coagulation profile, renal and liver function tests, blood grouping

• CONTRAINDICATIONS / FACTORS REQUIRING REASSESSMENT:

• Uncontrolled hyperthyroidism at time of surgery (must be rendered euthyroid with ATDs ± beta-blockade pre-operatively to prevent thyroid storm)

• Undisclosed pheochromocytoma in MEN2 (must be adrenalectomized first)

• Severe coagulopathy or anticoagulation not adequately bridged

• Active uncontrolled cardiopulmonary disease (ASA IV–V) — requires multidisciplinary optimization before proceeding

• Anaplastic thyroid carcinoma with unresectable mediastinal or vascular invasion (surgery is palliative and must be evaluated by a multidisciplinary tumor board; may be better served by EBRT + systemic therapy with lenvatinib/dabrafenib-trametinib combinations first)

SURGICAL APPROACHES — STANDARD TO ADVANCED:

1. OPEN TOTAL / NEAR-TOTAL THYROIDECTOMY (Gold Standard)

Performed through a 3–5 cm Kocher collar incision along a natural neck crease. Provides maximal exposure for large goiters, bulky nodal disease, or substernal extension. Continuous intraoperative neuromonitoring (C-IONM) with electromyographic endotracheal tubes (NIM Nerve Monitoring System, Medtronic) is the current gold standard to map and protect the RLN in real time. Near-infrared autofluorescence imaging (Fluobeam 800, Stryker Spy-PHY) identifies parathyroid glands intraoperatively, reducing rates of permanent hypoparathyroidism from ~3% to under 1% in published series. Energy-based sealing devices (Harmonic Focus+, Ethicon; LigaSure Maryland Jaw, Medtronic) replace traditional ties and reduce operative time and bleeding.

2. HEMITHYROIDECTOMY (LOBECTOMY ± ISTHMUSECTOMY)

Removal of one thyroid lobe, indicated for unilateral benign nodules, indeterminate cytology (Bethesda III–IV) with low-risk molecular profile, or small (<4 cm), low-risk unilateral PTC. Preserves contralateral lobe function, potentially avoiding lifelong thyroid hormone replacement in up to 78% of patients per ATA 2015 data.

3. MINIMALLY INVASIVE VIDEO-ASSISTED THYROIDECTOMY (MIVAT)

Developed by Miccoli et al. Uses a 15–20 mm central incision with 5 mm endoscopic ports and a 5 mm 30° endoscope. Indicated for thyroid volume ≤25 mL and nodule size ≤35 mm. Offers equivalent oncological outcomes with superior cosmetic results. Widely available at tertiary thyroid surgery centers in India and UAE.

4. ROBOTIC THYROIDECTOMY — REMOTE ACCESS APPROACHES

Avoids any visible neck scar entirely. Three principal platforms are used:

• Transaxillary Robotic Approach (TAR): da Vinci Surgical System via a 5–6 cm axillary incision, tunneled subcutaneously to the thyroid bed. Preferred in young patients, particularly women, for whom scar cosmesis is a priority.

• Bilateral Axillo-Breast Approach (BABA): Four robotic ports placed bilaterally in the axillae and periareolar breast region. Provides the best bilateral neck access and is the preferred robotic technique for bilateral thyroid disease.

• Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA): Three ports placed inside the lower lip vestibule — completely scarless externally. Growing evidence supports safety for goiters ≤10 cm and T1–T2 thyroid cancers without extrathyroidal extension. Available at select advanced centers in India (AIIMS Delhi, Apollo, Fortis) and UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai).

5. CENTRAL NECK DISSECTION (CND)

Level VI lymphadenectomy performed simultaneously with total thyroidectomy for clinically or sonographically node-positive central compartment disease. Prophylactic CND remains institution-dependent based on tumor size and surgeon expertise.

6. RADIOACTIVE IODINE (RAI / I-131) ADJUVANT THERAPY

Post-surgical adjuvant for intermediate-to-high-risk DTC after total thyroidectomy. Remnant ablation is performed after TSH stimulation (thyroid hormone withdrawal or recombinant human TSH — rhTSH, Thyrogen) and low-iodine diet. RAI reduces recurrence by 40–60% in high-risk DTC and facilitates Tg-based surveillance.

7. ADVANCED SYSTEMIC THERAPIES (for refractory/metastatic disease)

• Lenvatinib (Lenvima) and Sorafenib (Nexavar): multikinase inhibitors, first-line for radioiodine-refractory DTC

• Vandetanib (Caprelsa) and Cabozantinib (Cometriq): FDA-approved for progressive MTC

• Dabrafenib + Trametinib: BRAF V600E-mutated PTC or anaplastic thyroid carcinoma

• Selpercatinib (Retevmo) and Pralsetinib (Gavreto): RET-fusion positive thyroid cancers (approved by FDA and increasingly available in India/UAE)

STEP 1 — INITIAL TELECONSULTATION & CASE REVIEW (Weeks 1–2 before travel) Patient submits medical records, FNAC report, ultrasound images, and bloodwork to GAF Healthcare's medical concierge portal. A GAF-affiliated consultant endocrine surgeon reviews the case within 48 hours and provides a detailed second opinion, surgical recommendation, and personalized cost estimate. Molecular testing (ThyroSeq, Afirma) can be arranged remotely if FNAC cytology falls in the indeterminate Bethesda III–IV category.

STEP 2 — VISA & TRAVEL ARRANGEMENT (Weeks 2–3) For India: GAF Healthcare assists with the e-Medical Visa application (typically approved within 3–5 business days, valid for 60 days, extendable; allows 1 attendant on a co-medical visa). For UAE: Most nationalities receive a visa-on-arrival or pre-arranged medical visa through the hospital's international patient desk. GAF coordinates airport pickup, hotel or serviced-apartment booking near the hospital, and SIM card provisioning.

STEP 3 — PRE-OPERATIVE WORKUP ON ARRIVAL (Day 1–2) Patient is met at the airport by a GAF-assigned patient coordinator. Pre-op investigations are completed at the hospital outpatient department: repeat neck ultrasound (if > 3 months since last imaging), laryngoscopy, ECG, anesthesia fitness assessment, and baseline calcium/PTH. If the patient is hyperthyroid, a 2–4 week ATD optimization period (carbimazole or methimazole + propranolol + potassium iodide solution / Lugol's iodide for 10 days pre-op) may be required before surgical clearance. Euthyroid patients proceed directly to pre-operative preparation.

STEP 4 — SURGERY DAY (Day 3) Patient is admitted the morning of surgery. General anesthesia induction with EMG endotracheal tube placement for IONM. Operative time: 1.5–4 hours depending on approach (open vs. robotic vs. TOETVA) and extent of dissection (total thyroidectomy ± CND). Intraoperative frozen section histology available for margin assessment if required. RLN function is confirmed by IONM signal recovery before wound closure. Drain placement is at the surgeon's discretion.

STEP 5 — IMMEDIATE POST-OPERATIVE MONITORING (Day 3–4 in hospital) Patient is monitored in a stepdown unit for 4–6 hours post-extubation. Serum calcium, phosphate, and PTH are checked at 6 hours, 12 hours, and 24 hours post-operatively to detect hypoparathyroidism early. Oral calcium carbonate (1–2 g TID) and calcitriol (0.25–0.5 mcg BD) are routinely prescribed prophylactically for total thyroidectomy patients. Voice quality is assessed by the surgical team before discharge. Levothyroxine replacement is initiated on post-operative Day 1.

STEP 6 — HOSPITAL DISCHARGE & EARLY RECOVERY (Day 4–7 post-surgery) Patient is discharged with written instructions covering wound care, calcium/vitamin D supplementation, levothyroxine dosing, activity restrictions (no heavy lifting for 4 weeks), and dietary guidance. The first post-operative clinic visit is scheduled at Day 7 for wound check, suture/clip removal, and repeat calcium/PTH. Histopathology results are reviewed with the surgeon at this visit to confirm diagnosis and plan adjuvant RAI if indicated.

STEP 7 — FIT-TO-FLY ASSESSMENT (Week 2–3) For short-haul flights (< 4 hours), most patients are cleared to fly by Day 10–14 provided calcium levels are stable, wound is healing without complication, and voice is recovering satisfactorily. For long-haul intercontinental travel (> 6 hours), a 2–3 week minimum in-country stay is recommended to ensure parathyroid function has stabilized, levothyroxine dosing is appropriately established, and final histopathology with surgeon discussion is complete. GAF Healthcare arranges the formal fit-to-fly letter and transfers a complete medical dossier electronically to the patient's home physician.

STEP 8 — REMOTE FOLLOW-UP & SURVEILLANCE (Months 1–12 at home) GAF Healthcare coordinates virtual follow-up consultations at 6 weeks, 3 months, and 6 months post-discharge. The patient's home endocrinologist receives a structured hand-off report including operative notes, pathology report, TSH suppression targets, Tg baseline, and RAI planning if applicable. Annual neck ultrasound and serum Tg/Anti-Tg surveillance follows ATA risk-stratification guidelines.